About Daewoong Pharmaceutical
Daewoong Pharmaceutical is a publicly listed company based in Seoul (South Korea) founded in 1945. Therapies for gastrointestinal disorders and related diseases are developed. The company has 1,750 employees. Its chief executive, as recorded, is Seng-Ho Jeon. Its Indian entity Daewoong Pharmaceutical (India) Private Limited reported revenue of ₹4.87 Cr. Daewoong Pharmaceutical offers products and services including Daewoong Urusa, Impactamin Premium, Enblo, and Nabota. Its focus areas include Diversified Pharmaceuticals, Biopharma Outsourcing, CDMO and Diversified.
Company details
Daewoong Pharmaceutical was founded in 1945 in Seoul, South Korea, and operates in the pharmaceutical sector. Therapies for gastrointestinal disorders, diabetes, fibrotic diseases, and autoimmune conditions are developed by the company, including depot injections, liquid suspensions, and biologics. Medical devices are also manufactured. The lead candidate, DWP 14012, is under Phase I trials for gastroesophageal reflux disease. Manufacturing facilities are certified under ISO14001 and OHSAS18001 standards.
- Headquarters Seoul, South Korea
- Employees 1,750
- Stage Public
- SectorsHealthcare
- Website category Health · Pharmacy
- Email••••••••
- Phone•••• ••••
- Website daewoong.com/kr/main/index
- Social LinkedIn Instagram YouTube
- Legal Name Daewoong Pharmaceutical Co., Ltd.
- Indian entity revenue₹4.87 Cr
FY 2025 · -40% YoY
- Indian entity net loss-₹3.28 Cr
FY 2025 · -67% margin
- Indian entity EBITDA-₹2.39 Cr
FY 2025 · -49% margin
- Employee Count1,750
Associated legal entities of Daewoong Pharmaceutical
Daewoong Pharmaceutical operates through Daewoong Pharmaceutical (India) Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Daewoong Pharmaceutical (India) Private Limited CIN U24232TG2012FTC084511 | Active | 30 Nov 2012 | Hyderabad, Telangana | ₹4.9 Cr | 23 | 3 | View details |
Products & Services of Daewoong Pharmaceutical
Daewoong Pharmaceutical offers a comprehensive portfolio of products and services, including Daewoong Urusa, Impactamin Premium, Enblo, and Nabota.
Capsule for liver fatigue recovery and health support
Vitamin B supplement with customized formulations
Oral medication for blood sugar management
Botulinum toxin for medical treatments
Apps and channels of Daewoong Pharmaceutical
its YouTube channel Daewoong Pharmaceutical has 97.2K subscribers and 30 videos.
Videos from Daewoong Pharmaceutical
The most watched videos on Daewoong Pharmaceutical's YouTube channel, Daewoong Pharmaceutical (97.2K subscribers). Click a video to play it here.
More on Daewoong Pharmaceutical.
Board of directors of Daewoong Pharmaceutical (India) Private Limited (Daewoong Pharmaceutical)
Daewoong Pharmaceutical (India) Private Limited is the primary company behind Daewoong Pharmaceutical. The board of Daewoong Pharmaceutical (India) Private Limited currently have 3 directors; the longest-serving is Chung Hyun Song, appointed in 2016. 5 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Chung Hyun Song DIN 07357338 | Director | 08 Feb 2016 | 10 yrs 8 mo | Daewoong Pharmaceutical (India) Private Limited |
| Gwan Young Kim DIN 08104455 | Director | 09 Apr 2018 | 8 yrs 6 mo | Daewoong Pharmaceutical (India) Private Limited |
| Neelima Aryasomayajula DIN 10635719 | Additional Director | 21 May 2024 | 2 yrs 5 mo | Daewoong Pharmaceutical (India) Private Limited |
People of Daewoong Pharmaceutical
1 people are tracked at Daewoong Pharmaceutical (1 in leadership); the tracked headcount is 1,750.
| Name | Role | Group |
|---|---|---|
Seng-Ho Jeon | CEO | Leadership |
Complete people profiles for Daewoong Pharmaceutical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Daewoong Pharmaceutical
Daewoong Pharmaceutical is a publicly listed company on the KRX with ticker symbol 069620 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Oct 2010
- Listed onKRX: 069620
- Listed entityDaewoong Pharmaceutical Co., Ltd.
- Exchange sectorHealth technology
- ISINKR7069620003
- Share price106,600.00 KRW (-0.65% on the day) · 2026-10-14
- Market capitalisation1,234,622,712,517.00 KRW
- Price to earnings6.3
- EPS (diluted, trailing year)16,988.37 KRW
- Dividend yield0.56%
- Volume (last session)15,704
Financials of Daewoong Pharmaceutical
Figures of Daewoong Pharmaceutical (India) Private Limited, the primary company behind Daewoong Pharmaceutical, for FY 2025. Revenue was ₹4.87 Cr (-40% year on year). Net loss was -₹3.28 Cr (-67% margin). EBITDA was -₹2.39 Cr (-49% margin). Revenue has grown at a compounded annual rate of -15% over three years and -3% over five years.
- ₹4.87 CrRevenue · FY 2025 · -40% YoY
- -₹3.28 CrNet loss · -67% margin
- -₹2.39 CrEBITDA · -49% margin
- ₹2.86 CrPaid-up capital
- 23Employees (provident fund records)
- -15%Revenue CAGR, 3 years
- -3%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1,570.00B KRW | 195.86B KRW | 245.78B KRW |
| 2024 | 1,420.00B KRW | 24.73B KRW | 193.38B KRW |
| 2023 | 1,380.00B KRW | 121.74B KRW | 163.82B KRW |
| 2022 | 1,280.00B KRW | 42.24B KRW | 133.81B KRW |
| 2021 | 1,150.00B KRW | 24.51B KRW | 127.82B KRW |
Balance sheet, profit and loss, cash flow and ratios of Daewoong Pharmaceutical (India) Private Limited are on its company page.
Detailed financial statements for Daewoong Pharmaceutical
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Daewoong Pharmaceutical
The website of Daewoong Pharmaceutical (daewoong.com) receives about 7.7K visits a month and ranks #4,360,353 among all websites worldwide, #4,377 in Pharmacy.
- Monthly visits7.7K
▲ 80.5% vs previous month
- Unique visitors1.7K
per month
- Global rank#4,360,353
among all websites
- Category rank#4,377
Health · Pharmacy
- Bounce rate41%
- Pages per visit1.5
- Average visit18 sec
- DevicesDesktop 39% · Mobile 61%
Websites whose visitors overlap most with Daewoong Pharmaceutical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
otsuka.co.id | otsuka.co.id | 100% | #328,348 | – | |
| sanbe-farma.com | 60% | #2,380,886 | View details | ||
| daewonpharm.com | 60% | 95.4K | View details | ||
dexa-medica.com | dexa-medica.com | 59% | – | ||
evaluategroup.com | evaluategroup.com | 58% | #14,639,274 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Daewoong Pharmaceutical
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Daewoong Pharmaceutical
Complete news archive for Daewoong Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Daewoong Pharmaceutical
Daewoong Pharmaceutical was founded in 1945.
Daewoong Pharmaceutical is headquartered in Seoul, South Korea.
Seng-Ho Jeon is the CEO of Daewoong Pharmaceutical, as recorded in our data.
Daewoong Pharmaceutical has 1,750 employees.
The primary company behind Daewoong Pharmaceutical, Daewoong Pharmaceutical (India) Private Limited, reported revenue of ₹4.87 Cr for FY 2025, down 40% year on year.
Daewoong Pharmaceutical was founded in 1945 in Seoul, South Korea, and operates in the pharmaceutical sector. Therapies for gastrointestinal disorders, diabetes, fibrotic diseases, and autoimmune conditions are developed by the company, including depot injections, liquid suspensions, and biologics. Medical devices are also manufactured. The lead candidate, DWP 14012, is under Phase I trials for gastroesophageal reflux disease. Manufacturing facilities are certified under ISO14001 and OHSAS18001 standards.
Daewoong Pharmaceutical offers Daewoong Urusa, Impactamin Premium, Enblo, and Nabota.
Yes, Daewoong Pharmaceutical is publicly traded on KRX under the ticker symbol 069620.
Daewoong Pharmaceutical operates through Daewoong Pharmaceutical (India) Private Limited.
The legal entities of Daewoong Pharmaceutical currently have 3 directors, including Neelima Aryasomayajula, Gwan Young Kim, Chung Hyun Song.